Jamshri Realty [JAMSHRI] vs Poly Medicure [POLYMED] Detailed Stock Comparison
Jamshri Realty
BSE
Loading...
Poly Medicure
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Jamshri Realty wins in 8 metrics, Poly Medicure wins in 6 metrics, with 0 ties. Jamshri Realty appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Jamshri Realty | Poly Medicure | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 0.00 | 56.51 | Jamshri Realty |
| Price-to-Book Ratio | N/A | 7.17 | N/A |
| Debt-to-Equity Ratio | -9.40 | 6.52 | Jamshri Realty |
| PEG Ratio | N/A | 250.96 | N/A |
| EV/EBITDA | 4,076.39 | 41.50 | Poly Medicure |
| Profit Margin (TTM) | 100.00% | 20.28% | Jamshri Realty |
| Operating Margin (TTM) | 24.01% | 22.33% | Jamshri Realty |
| EBITDA Margin (TTM) | 24.01% | 22.33% | Jamshri Realty |
| Return on Equity | 23.92% | 15.99% | Jamshri Realty |
| Return on Assets (TTM) | -2.37% | 9.16% | Poly Medicure |
| Free Cash Flow (TTM) | $10.56M | $-906.06M | Jamshri Realty |
| Dividend Yield | N/A | 0.14% | N/A |
| 1-Year Return | -49.57% | 2.56% | Poly Medicure |
| Price-to-Sales Ratio (TTM) | 1,560.57 | 11.70 | Poly Medicure |
| Enterprise Value | $110.21B | $188.15B | Poly Medicure |
| EV/Revenue Ratio | 1,567.43 | 11.27 | Poly Medicure |
| Gross Profit Margin (TTM) | 100.00% | 66.56% | Jamshri Realty |
| Revenue per Share (TTM) | N/A | $168 | N/A |
| Earnings per Share (Diluted) | N/A | $34.11 | N/A |
| Beta (Stock Volatility) | N/A | 0.04 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Jamshri Realty vs Poly Medicure Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Jamshri Realty | -2.07% | -6.08% | -8.02% | 11.34% | -9.24% | -23.14% |
| Poly Medicure | -0.45% | -1.09% | -12.79% | -27.94% | -17.66% | -28.08% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Jamshri Realty | -49.57% | -96.97% | -96.23% | -96.54% | -95.42% | -96.93% |
| Poly Medicure | 2.56% | 163.05% | 384.64% | 765.20% | 5,814.08% | 5,814.08% |
Performance & Financial Health Analysis: Jamshri Realty vs Poly Medicure
| Metric | JAMSHRI | POLYMED |
|---|---|---|
| Market Information | ||
| Market Cap | ₹109.73B | ₹195.30B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 3,134 | 143,078 |
| 90 Day Avg. Volume | 4,333 | 126,420 |
| Last Close | ₹106.60 | ₹1,927.40 |
| 52 Week Range | ₹72.35 - ₹295.65 | ₹1,858.00 - ₹3,357.80 |
| % from 52W High | -63.94% | -42.60% |
| All-Time High | ₹19,527.35 (Aug 05, 2024) | ₹3,357.80 (Oct 28, 2024) |
| % from All-Time High | -99.45% | -42.60% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.11% | 0.17% |
| Quarterly Earnings Growth | 0.06% | 0.34% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.20% |
| Operating Margin (TTM) | 0.24% | 0.22% |
| Return on Equity (TTM) | 0.24% | 0.16% |
| Debt to Equity (MRQ) | -9.40 | 6.52 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | N/A | ₹268.63 |
| Cash per Share (MRQ) | N/A | ₹117.33 |
| Operating Cash Flow (TTM) | ₹8.59M | ₹2.40B |
| Levered Free Cash Flow (TTM) | ₹-12,380,000 | ₹-1,657,084,800 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.14% |
| Last 12-Month Dividend | N/A | ₹3.00 |
Valuation & Enterprise Metrics Analysis: Jamshri Realty vs Poly Medicure
| Metric | JAMSHRI | POLYMED |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 0.00 | 56.51 |
| Forward P/E | 0.00 | 250.96 |
| PEG Ratio | N/A | 250.96 |
| Price to Sales (TTM) | 1,560.57 | 11.70 |
| Price to Book (MRQ) | N/A | 7.17 |
| Market Capitalization | ||
| Market Capitalization | ₹109.73B | ₹195.30B |
| Enterprise Value | ₹110.21B | ₹188.15B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1,567.43 | 11.27 |
| Enterprise to EBITDA | 4,076.39 | 41.50 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.04 |
| Book Value per Share (MRQ) | N/A | ₹268.63 |
Financial Statements Comparison: Jamshri Realty vs Poly Medicure
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JAMSHRI | POLYMED |
|---|---|---|
| Revenue/Sales | ₹16.84M | ₹4.41B |
| Cost of Goods Sold | ₹0 | ₹1.47B |
| Gross Profit | ₹16.84M | ₹2.93B |
| Research & Development | N/A | ₹112.93M |
| Operating Income (EBIT) | ₹-1.50M | ₹984.32M |
| EBITDA | ₹5.09M | ₹1.46B |
| Pre-Tax Income | ₹-4.17M | ₹1.23B |
| Income Tax | ₹0 | ₹310.15M |
| Net Income (Profit) | ₹-4.64M | ₹918.34M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JAMSHRI | POLYMED |
|---|---|---|
| Cash & Equivalents | ₹3.56M | ₹86.99M |
| Total Current Assets | ₹34.34M | ₹19.17B |
| Total Current Liabilities | ₹127.36M | ₹3.70B |
| Long-Term Debt | ₹445.29M | ₹7.71M |
| Total Shareholders Equity | ₹-51.76M | ₹27.66B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹239.46M | ₹10.41B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JAMSHRI | POLYMED |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JAMSHRI | POLYMED |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 3,134 | 143,078 |
| Average Daily Volume (90 Day) | 4,333 | 126,420 |
| Shares Outstanding | 6.99M | 101.33M |
| Float Shares | N/A | 33.77M |
| % Held by Insiders | N/A | 0.67% |
| % Held by Institutions | N/A | 0.19% |
Dividend Analysis & Yield Comparison: Jamshri Realty vs Poly Medicure
| Metric | JAMSHRI | POLYMED |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹3.00 |
| Last 12-Month Dividend Yield | N/A | 0.14% |
| 3-Year Avg Annual Dividend | N/A | ₹2.83 |
| 3-Year Avg Dividend Yield | N/A | 0.21% |
| 3-Year Total Dividends | N/A | ₹8.50 |
| Ex-Dividend Date | N/A | Sep 19, 2024 |